Related Experiment Video
Updated: Oct 30, 2025
Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
Published on: August 9, 2022
Viral Control of Glioblastoma
Nicole Mihelson1, Dorian B McGavern1
1Viral Immunology & Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 5N240C, Bethesda, MD 20892, USA.
Abstract:
Glioblastoma multiforme (GBM) is a universally lethal cancer of the central nervous system. Patients with GBM have a median survival of 14 months and a 5-year survival of less than 5%, a grim statistic that has remained unchanged over the last 50 years. GBM is intransigent for a variety of reasons. The immune system has a difficult time mounting a response against glioblastomas because they reside in the brain (an immunologically dampened compartment) and generate few neoantigens relative to other cancers. Glioblastomas inhabit the brain like sand in the grass and display a high degree of intra- and inter-tumoral heterogeneity, impeding efforts to therapeutically target a single pathway. Of all potential therapeutic strategies to date, virotherapy offers the greatest chance of counteracting each of the obstacles mounted by GBM. Virotherapy can xenogenize a tumor that is deft at behaving like "self", triggering adaptive immune recognition in an otherwise immunologically quiet compartment. Viruses can also directly lyse tumor cells, creating damage and further stimulating secondary immune reactions that are detrimental to tumor growth. In this review, we summarize the basic immune mechanisms underpinning GBM immune evasion and the recent successes achieved using virotherapies.
Insights
Virotherapy offers a promising approach to combat glioblastoma multiforme (GBM), a deadly brain cancer. This strategy leverages viruses to stimulate immune responses and directly attack tumor cells, overcoming GBM
Area of Science:
- Neuro-oncology
- Immunotherapy
- Virology
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor patient survival rates.
- GBM evades immune detection due to the brain's immune-suppressed environment and tumor heterogeneity.
- Current treatments have limited efficacy, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the immune evasion mechanisms employed by GBM.
- To explore the potential of virotherapy as a treatment for GBM.
- To summarize recent advancements in GBM virotherapy.
Main Methods:
- Review of scientific literature on GBM immunology and virotherapy.
- Analysis of immune mechanisms underlying GBM development.
- Evaluation of virotherapy's efficacy in preclinical and clinical studies.
Main Results:
- GBM utilizes immune privilege and low neoantigen presentation to evade the immune system.
- Virotherapy can overcome immune evasion by "xenogenizing" tumors and triggering immune recognition.
- Oncolytic viruses directly lyse GBM cells, inducing secondary anti-tumor immune responses.
Conclusions:
- Virotherapy presents a potent strategy to address GBM's immune evasion and heterogeneity.
- Viral-mediated tumor lysis and immune stimulation offer a promising therapeutic avenue for glioblastoma.
- Further research into virotherapy holds significant potential for improving GBM patient outcomes.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...